Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 6Neoplasms 4Myelodysplastic Syndromes 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Stable Colorectal Carcinoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 19romidepsin 15fludarabine phosphate 13Whole-Body Irradiation 13Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Doxorubicin 11Vincristine 10Prednisone 10Cyclosporine 1010-propargyl-10-deazaaminopterin 10Gemcitabine 8Etoposide 8Alemtuzumab 8Bortezomib 6Dexamethasone 5Busulfan 5Brentuximab Vedotin 5mogamulizumab 4denileukin diftitox 4darinaparsin 4Vitamin B 12 4Nivolumab 4Lenalidomide 4Folic Acid 4Carboplatin 4carfilzomib 3belinostat 3Tacrolimus 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Peripheral × cc-486 × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡